Morgan Stanley lowered the firm’s price target on Healthpeak to $22 from $25 and keeps an Equal Weight rating on the shares. Senior housing demand is recovering ahead of expectations and the firm sees “another potential leg of outperformance,” says the analyst, who adds that the firm is more cautious on life sciences exposure among its REIT coverage in the near-term given elevated supply and slowing demand.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PEAK:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 31 – August 4, 2023
- Healthpeak narrows 2023 AFFO view to $1.73-$1.77 from $1.71-$1.77
- Healthpeak reports Q2 adjusted FFO 40c, consensus 44c
- Healthpeak Properties Reports Second Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock
- Healthpeak price target lowered to $32 from $33 at Barclays